Bladder Cancer Coverage from Every Angle

Daniel P. Petrylak, MD, on Enfortumab Vedotin-ejfv as Monotherapy for Bladder Cancer

Posted: Tuesday, February 22, 2022

Daniel P. Petrylak, MD, of Yale Cancer Center, discusses his observations, based on recent study results, about the role of neoadjuvant single-agent therapy with enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer who are not eligible for cisplatin.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.